Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 59 entries
Sorted by: Best Match Show Resources per page
Benefits of switching from latanoprost to preservative-free tafluprost eye drops: a meta-analysis of two Phase IIIb clinical trials.

Clinical ophthalmology (Auckland, N.Z.)

Uusitalo H, Egorov E, Kaarniranta K, Astakhov Y, Ropo A.
PMID: 27041987
Clin Ophthalmol. 2016 Mar 15;10:445-54. doi: 10.2147/OPTH.S91402. eCollection 2016.

INTRODUCTION: Glaucoma patients frequently exhibit ocular surface side effects during treatment with prostaglandin eye drops. The present work investigated whether glaucoma patients suffering from signs and symptoms of ocular surface disease while using preserved latanoprost eye drops benefited from...

Cite
Uusitalo H, Egorov E, Kaarniranta K, et al. Benefits of switching from latanoprost to preservative-free tafluprost eye drops: a meta-analysis of two Phase IIIb clinical trials. Clin Ophthalmol. 2016;10:445-54doi: 10.2147/OPTH.S91402.
Uusitalo, H., Egorov, E., Kaarniranta, K., Astakhov, Y., & Ropo, A. (2016). Benefits of switching from latanoprost to preservative-free tafluprost eye drops: a meta-analysis of two Phase IIIb clinical trials. Clinical ophthalmology (Auckland, N.Z.), 10445-54. https://doi.org/10.2147/OPTH.S91402
Uusitalo, Hannu, et al. "Benefits of switching from latanoprost to preservative-free tafluprost eye drops: a meta-analysis of two Phase IIIb clinical trials." Clinical ophthalmology (Auckland, N.Z.) vol. 10 (2016): 445-54. doi: https://doi.org/10.2147/OPTH.S91402
Uusitalo H, Egorov E, Kaarniranta K, Astakhov Y, Ropo A. Benefits of switching from latanoprost to preservative-free tafluprost eye drops: a meta-analysis of two Phase IIIb clinical trials. Clin Ophthalmol. 2016 Mar 15;10:445-54. doi: 10.2147/OPTH.S91402. eCollection 2016. PMID: 27041987; PMCID: PMC4801127.
Copy Download .nbib Format: NLM
Endoscopic dacryocystorhinostomy as treatment for lower lacrimal pathway obstructions in adults: Review article.

Allergy & rhinology (Providence, R.I.)

Penttilä E, Smirnov G, Tuomilehto H, Kaarniranta K, Seppä J.
PMID: 25860166
Allergy Rhinol (Providence). 2015 Jan;6(1):12-9. doi: 10.2500/ar.2015.6.0116.

Obstruction of the lacrimal pathway is manifested by epiphora, infection, and blurred vision as well as ocular and facial pain. Conservative treatments only achieve temporary relief of symptoms, thus surgery is the treatment of choice. Dacryocystorhinostomy (DCR) is recognized...

Cite
Penttilä E, Smirnov G, Tuomilehto H, et al. Endoscopic dacryocystorhinostomy as treatment for lower lacrimal pathway obstructions in adults: Review article. Allergy Rhinol (Providence). 2015;6(1):12-9doi: 10.2500/ar.2015.6.0116.
Penttilä, E., Smirnov, G., Tuomilehto, H., Kaarniranta, K., & Seppä, J. (2015). Endoscopic dacryocystorhinostomy as treatment for lower lacrimal pathway obstructions in adults: Review article. Allergy & rhinology (Providence, R.I.), 6(1), 12-9. https://doi.org/10.2500/ar.2015.6.0116
Penttilä, Elina, et al. "Endoscopic dacryocystorhinostomy as treatment for lower lacrimal pathway obstructions in adults: Review article." Allergy & rhinology (Providence, R.I.) vol. 6,1 (2015): 12-9. doi: https://doi.org/10.2500/ar.2015.6.0116
Penttilä E, Smirnov G, Tuomilehto H, Kaarniranta K, Seppä J. Endoscopic dacryocystorhinostomy as treatment for lower lacrimal pathway obstructions in adults: Review article. Allergy Rhinol (Providence). 2015 Jan;6(1):12-9. doi: 10.2500/ar.2015.6.0116. PMID: 25860166; PMCID: PMC4388871.
Copy Download .nbib Format: NLM
Changes in neurophysiologic markers of visual processing following beneficial anti-VEGF treatment in macular degeneration.

Clinical ophthalmology (Auckland, N.Z.)

Vottonen P, Kaarniranta K, Pääkkönen A, Tarkka IM.
PMID: 23467427
Clin Ophthalmol. 2013;7:437-42. doi: 10.2147/OPTH.S40427. Epub 2013 Feb 27.

PURPOSE: Antivascular endothelial growth factor (VEGF) agents have been shown to improve visual acuity and prevent vision loss in exudative age-related macular degeneration. As the vision improves relatively quickly in response to intravitreal injections, we wanted to know whether...

Cite
Vottonen P, Kaarniranta K, Pääkkönen A, et al. Changes in neurophysiologic markers of visual processing following beneficial anti-VEGF treatment in macular degeneration. Clin Ophthalmol. 2013;7:437-42doi: 10.2147/OPTH.S40427.
Vottonen, P., Kaarniranta, K., Pääkkönen, A., & Tarkka, I. M. (2013). Changes in neurophysiologic markers of visual processing following beneficial anti-VEGF treatment in macular degeneration. Clinical ophthalmology (Auckland, N.Z.), 7437-42. https://doi.org/10.2147/OPTH.S40427
Vottonen, Pasi, et al. "Changes in neurophysiologic markers of visual processing following beneficial anti-VEGF treatment in macular degeneration." Clinical ophthalmology (Auckland, N.Z.) vol. 7 (2013): 437-42. doi: https://doi.org/10.2147/OPTH.S40427
Vottonen P, Kaarniranta K, Pääkkönen A, Tarkka IM. Changes in neurophysiologic markers of visual processing following beneficial anti-VEGF treatment in macular degeneration. Clin Ophthalmol. 2013;7:437-42. doi: 10.2147/OPTH.S40427. Epub 2013 Feb 27. PMID: 23467427; PMCID: PMC3589120.
Copy Download .nbib Format: NLM
A prospective study on postoperative pain after cataract surgery.

Clinical ophthalmology (Auckland, N.Z.)

Porela-Tiihonen S, Kaarniranta K, Kokki M, Purhonen S, Kokki H.
PMID: 23885165
Clin Ophthalmol. 2013;7:1429-35. doi: 10.2147/OPTH.S47576. Epub 2013 Jul 15.

PURPOSE: To evaluate postoperative pain and early recovery in cataract patients.PATIENTS AND METHODS: A total of 201 patients who underwent elective first eye cataract extraction surgery were enrolled, and 196 were included in the final analysis. The study design...

Cite
Porela-Tiihonen S, Kaarniranta K, Kokki M, et al. A prospective study on postoperative pain after cataract surgery. Clin Ophthalmol. 2013;7:1429-35doi: 10.2147/OPTH.S47576.
Porela-Tiihonen, S., Kaarniranta, K., Kokki, M., Purhonen, S., & Kokki, H. (2013). A prospective study on postoperative pain after cataract surgery. Clinical ophthalmology (Auckland, N.Z.), 71429-35. https://doi.org/10.2147/OPTH.S47576
Porela-Tiihonen, Susanna, et al. "A prospective study on postoperative pain after cataract surgery." Clinical ophthalmology (Auckland, N.Z.) vol. 7 (2013): 1429-35. doi: https://doi.org/10.2147/OPTH.S47576
Porela-Tiihonen S, Kaarniranta K, Kokki M, Purhonen S, Kokki H. A prospective study on postoperative pain after cataract surgery. Clin Ophthalmol. 2013;7:1429-35. doi: 10.2147/OPTH.S47576. Epub 2013 Jul 15. PMID: 23885165; PMCID: PMC3716556.
Copy Download .nbib Format: NLM
Lysosomal destabilization activates the NLRP3 inflammasome in human umbilical vein endothelial cells (HUVECs).

Journal of cell communication and signaling

Kinnunen K, Piippo N, Loukovaara S, Hytti M, Kaarniranta K, Kauppinen A.
PMID: 28547650
J Cell Commun Signal. 2017 Sep;11(3):275-279. doi: 10.1007/s12079-017-0396-4. Epub 2017 May 25.

Inflammation is a crucial component in the pathogenesis of many vascular diseases, such as atherosclerosis and diabetes. Inflammasomes are intracellular signalling complexes whose activation promotes inflammation. Nucleotide-binding domain and Leucine-rich repeat Receptor containing a Pyrin domain 3 (NLRP3) is...

Cite
Kinnunen K, Piippo N, Loukovaara S, et al. Lysosomal destabilization activates the NLRP3 inflammasome in human umbilical vein endothelial cells (HUVECs). J Cell Commun Signal. 2017;11(3):275-279doi: 10.1007/s12079-017-0396-4.
Kinnunen, K., Piippo, N., Loukovaara, S., Hytti, M., Kaarniranta, K., & Kauppinen, A. (2017). Lysosomal destabilization activates the NLRP3 inflammasome in human umbilical vein endothelial cells (HUVECs). Journal of cell communication and signaling, 11(3), 275-279. https://doi.org/10.1007/s12079-017-0396-4
Kinnunen, K, et al. "Lysosomal destabilization activates the NLRP3 inflammasome in human umbilical vein endothelial cells (HUVECs)." Journal of cell communication and signaling vol. 11,3 (2017): 275-279. doi: https://doi.org/10.1007/s12079-017-0396-4
Kinnunen K, Piippo N, Loukovaara S, Hytti M, Kaarniranta K, Kauppinen A. Lysosomal destabilization activates the NLRP3 inflammasome in human umbilical vein endothelial cells (HUVECs). J Cell Commun Signal. 2017 Sep;11(3):275-279. doi: 10.1007/s12079-017-0396-4. Epub 2017 May 25. PMID: 28547650; PMCID: PMC5559399.
Copy Download .nbib Format: NLM
Correlation between the rate of intravitreal injections, use of aflibercept as a second-line treatment and visual impairment for wet AMD in Finland.

Acta ophthalmologica

Karesvuo P, Hakkala L, Kaarniranta K, Uusitalo H, Ojamo M, Tuuminen R.
PMID: 32096347
Acta Ophthalmol. 2020 Feb 24; doi: 10.1111/aos.14376. Epub 2020 Feb 24.

PURPOSE: To correlate the rate of intravitreal anti-VEGF injections and the use of aflibercept as a second-line treatment with visual impairment throughout Finland.METHODS: Information related to anti-VEGF treatment, proportions of bevacizumab and aflibercept and new visual impairments due to...

Cite
Karesvuo P, Hakkala L, Kaarniranta K, et al. Correlation between the rate of intravitreal injections, use of aflibercept as a second-line treatment and visual impairment for wet AMD in Finland. Acta Ophthalmol. 2020;doi: 10.1111/aos.14376.
Karesvuo, P., Hakkala, L., Kaarniranta, K., Uusitalo, H., Ojamo, M., & Tuuminen, R. (2020). Correlation between the rate of intravitreal injections, use of aflibercept as a second-line treatment and visual impairment for wet AMD in Finland. Acta ophthalmologica, . https://doi.org/10.1111/aos.14376
Karesvuo, Petteri, et al. "Correlation between the rate of intravitreal injections, use of aflibercept as a second-line treatment and visual impairment for wet AMD in Finland." Acta ophthalmologica vol. (2020). doi: https://doi.org/10.1111/aos.14376
Karesvuo P, Hakkala L, Kaarniranta K, Uusitalo H, Ojamo M, Tuuminen R. Correlation between the rate of intravitreal injections, use of aflibercept as a second-line treatment and visual impairment for wet AMD in Finland. Acta Ophthalmol. 2020 Feb 24; doi: 10.1111/aos.14376. Epub 2020 Feb 24. PMID: 32096347.
Copy Download .nbib Format: NLM
Serum Levels of Plasmalogens and Fatty Acid Metabolites Associate with Retinal Microangiopathy in Participants from the Finnish Diabetes Prevention Study.

Nutrients

de Mello VD, Selander T, Lindström J, Tuomilehto J, Uusitupa M, Kaarniranta K.
PMID: 34960007
Nutrients. 2021 Dec 14;13(12). doi: 10.3390/nu13124452.

Diabetic retinopathy (DR) is the most common microvascular complication of diabetes, and retinal microaneurysms (MA) are one of the first detected abnormalities associated with DR. We recently showed elevated serum triglyceride levels to be associated with the development of...

Cite
de Mello VD, Selander T, Lindström J, et al. Serum Levels of Plasmalogens and Fatty Acid Metabolites Associate with Retinal Microangiopathy in Participants from the Finnish Diabetes Prevention Study. Nutrients. 2021;13(12)doi: 10.3390/nu13124452.
de Mello, V. D., Selander, T., Lindström, J., Tuomilehto, J., Uusitupa, M., & Kaarniranta, K. (2021). Serum Levels of Plasmalogens and Fatty Acid Metabolites Associate with Retinal Microangiopathy in Participants from the Finnish Diabetes Prevention Study. Nutrients, 13(12), . https://doi.org/10.3390/nu13124452
de Mello, Vanessa Derenji, et al. "Serum Levels of Plasmalogens and Fatty Acid Metabolites Associate with Retinal Microangiopathy in Participants from the Finnish Diabetes Prevention Study." Nutrients vol. 13,12 (2021). doi: https://doi.org/10.3390/nu13124452
de Mello VD, Selander T, Lindström J, Tuomilehto J, Uusitupa M, Kaarniranta K. Serum Levels of Plasmalogens and Fatty Acid Metabolites Associate with Retinal Microangiopathy in Participants from the Finnish Diabetes Prevention Study. Nutrients. 2021 Dec 14;13(12). doi: 10.3390/nu13124452. PMID: 34960007.
Copy Download .nbib Format: NLM
Inhibition of prolyl oligopeptidase: A promising pathway to prevent the progression of age-related macular degeneration.

Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie

Hellinen L, Koskela A, Vattulainen E, Liukkonen M, Wegler C, Treyer A, Handin N, Svensson R, Myöhänen T, Poso A, Kaarniranta K, Artursson P, Urtti A.
PMID: 34891119
Biomed Pharmacother. 2021 Dec 07;146:112501. doi: 10.1016/j.biopha.2021.112501. Epub 2021 Dec 07.

Dry age-related macular degeneration (AMD) is a currently untreatable vision threatening disease. Impaired proteasomal clearance and autophagy in the retinal pigment epithelium (RPE) and subsequent photoreceptor damage are connected with dry AMD, but detailed pathophysiology is still unclear. In...

Cite
Hellinen L, Koskela A, Vattulainen E, et al. Inhibition of prolyl oligopeptidase: A promising pathway to prevent the progression of age-related macular degeneration. Biomed Pharmacother. 2021;146:112501doi: 10.1016/j.biopha.2021.112501.
Hellinen, L., Koskela, A., Vattulainen, E., Liukkonen, M., Wegler, C., Treyer, A., Handin, N., Svensson, R., Myöhänen, T., Poso, A., Kaarniranta, K., Artursson, P., & Urtti, A. (2021). Inhibition of prolyl oligopeptidase: A promising pathway to prevent the progression of age-related macular degeneration. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 146112501. https://doi.org/10.1016/j.biopha.2021.112501
Hellinen, Laura, et al. "Inhibition of prolyl oligopeptidase: A promising pathway to prevent the progression of age-related macular degeneration." Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie vol. 146 (2021): 112501. doi: https://doi.org/10.1016/j.biopha.2021.112501
Hellinen L, Koskela A, Vattulainen E, Liukkonen M, Wegler C, Treyer A, Handin N, Svensson R, Myöhänen T, Poso A, Kaarniranta K, Artursson P, Urtti A. Inhibition of prolyl oligopeptidase: A promising pathway to prevent the progression of age-related macular degeneration. Biomed Pharmacother. 2021 Dec 07;146:112501. doi: 10.1016/j.biopha.2021.112501. Epub 2021 Dec 07. PMID: 34891119.
Copy Download .nbib Format: NLM
The state of your journal Acta Ophthalmologica 2020.

Acta ophthalmologica

Kaarniranta K, Stefánsson E.
PMID: 34423912
Acta Ophthalmol. 2021 Aug;99(5):467-469. doi: 10.1111/aos.14915.

No abstract available.

Cite
Kaarniranta K, Stefánsson E. The state of your journal Acta Ophthalmologica 2020. Acta Ophthalmol. 2021;99(5):467-469doi: 10.1111/aos.14915.
Kaarniranta, K., & Stefánsson, E. (2021). The state of your journal Acta Ophthalmologica 2020. Acta ophthalmologica, 99(5), 467-469. https://doi.org/10.1111/aos.14915
Kaarniranta, Kai, and Stefánsson, Einar. "The state of your journal Acta Ophthalmologica 2020." Acta ophthalmologica vol. 99,5 (2021): 467-469. doi: https://doi.org/10.1111/aos.14915
Kaarniranta K, Stefánsson E. The state of your journal Acta Ophthalmologica 2020. Acta Ophthalmol. 2021 Aug;99(5):467-469. doi: 10.1111/aos.14915. PMID: 34423912.
Copy Download .nbib Format: NLM
Inhibition of prolyl oligopeptidase: A promising pathway to prevent the progression of age-related macular degeneration.

Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie

Hellinen L, Koskela A, Vattulainen E, Liukkonen M, Wegler C, Treyer A, Handin N, Svensson R, Myöhänen T, Poso A, Kaarniranta K, Artursson P, Urtti A.
PMID: 34891119
Biomed Pharmacother. 2021 Dec 07;146:112501. doi: 10.1016/j.biopha.2021.112501. Epub 2021 Dec 07.

Dry age-related macular degeneration (AMD) is a currently untreatable vision threatening disease. Impaired proteasomal clearance and autophagy in the retinal pigment epithelium (RPE) and subsequent photoreceptor damage are connected with dry AMD, but detailed pathophysiology is still unclear. In...

Cite
Hellinen L, Koskela A, Vattulainen E, et al. Inhibition of prolyl oligopeptidase: A promising pathway to prevent the progression of age-related macular degeneration. Biomed Pharmacother. 2021;146:112501doi: 10.1016/j.biopha.2021.112501.
Hellinen, L., Koskela, A., Vattulainen, E., Liukkonen, M., Wegler, C., Treyer, A., Handin, N., Svensson, R., Myöhänen, T., Poso, A., Kaarniranta, K., Artursson, P., & Urtti, A. (2021). Inhibition of prolyl oligopeptidase: A promising pathway to prevent the progression of age-related macular degeneration. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 146112501. https://doi.org/10.1016/j.biopha.2021.112501
Hellinen, Laura, et al. "Inhibition of prolyl oligopeptidase: A promising pathway to prevent the progression of age-related macular degeneration." Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie vol. 146 (2021): 112501. doi: https://doi.org/10.1016/j.biopha.2021.112501
Hellinen L, Koskela A, Vattulainen E, Liukkonen M, Wegler C, Treyer A, Handin N, Svensson R, Myöhänen T, Poso A, Kaarniranta K, Artursson P, Urtti A. Inhibition of prolyl oligopeptidase: A promising pathway to prevent the progression of age-related macular degeneration. Biomed Pharmacother. 2021 Dec 07;146:112501. doi: 10.1016/j.biopha.2021.112501. Epub 2021 Dec 07. PMID: 34891119.
Copy Download .nbib Format: NLM
DICER1 in the Pathogenesis of Age-related Macular Degeneration (AMD) - .

Aging and disease

Kaarniranta K, Pawlowska E, Szczepanska J, Blasiak J.
PMID: 32765950
Aging Dis. 2020 Jul 23;11(4):851-862. doi: 10.14336/AD.2019.0809. eCollection 2020 Jul.

DICER1 deficiency in the retinal pigment epithelium (RPE) was associated with the accumulation of

Cite
Kaarniranta K, Pawlowska E, Szczepanska J, et al. DICER1 in the Pathogenesis of Age-related Macular Degeneration (AMD) - . Aging Dis. 2020;11(4):851-862doi: 10.14336/AD.2019.0809.
Kaarniranta, K., Pawlowska, E., Szczepanska, J., & Blasiak, J. (2020). DICER1 in the Pathogenesis of Age-related Macular Degeneration (AMD) - . Aging and disease, 11(4), 851-862. https://doi.org/10.14336/AD.2019.0809
Kaarniranta, Kai, et al. "DICER1 in the Pathogenesis of Age-related Macular Degeneration (AMD) - ." Aging and disease vol. 11,4 (2020): 851-862. doi: https://doi.org/10.14336/AD.2019.0809
Kaarniranta K, Pawlowska E, Szczepanska J, Blasiak J. DICER1 in the Pathogenesis of Age-related Macular Degeneration (AMD) - . Aging Dis. 2020 Jul 23;11(4):851-862. doi: 10.14336/AD.2019.0809. eCollection 2020 Jul. PMID: 32765950; PMCID: PMC7390522.
Copy Download .nbib Format: NLM
Hypoxia/ischemia impairs CD33 (Siglec-3)/TREM2 signaling: Potential role in Alzheimer's pathogenesis.

Neurochemistry international

Salminen A, Kaarniranta K, Kauppinen A.
PMID: 34530055
Neurochem Int. 2021 Nov;150:105186. doi: 10.1016/j.neuint.2021.105186. Epub 2021 Sep 13.

Recent genetic and molecular studies have indicated that the innate immune system, especially microglia, have a crucial role in the accumulation of β-amyloid plaques in Alzheimer's disease (AD). In particular, the CD33 receptor, also called Siglec-3, inhibits the TREM2...

Cite
Salminen A, Kaarniranta K, Kauppinen A. Hypoxia/ischemia impairs CD33 (Siglec-3)/TREM2 signaling: Potential role in Alzheimer's pathogenesis. Neurochem Int. 2021;150:105186doi: 10.1016/j.neuint.2021.105186.
Salminen, A., Kaarniranta, K., & Kauppinen, A. (2021). Hypoxia/ischemia impairs CD33 (Siglec-3)/TREM2 signaling: Potential role in Alzheimer's pathogenesis. Neurochemistry international, 150105186. https://doi.org/10.1016/j.neuint.2021.105186
Salminen, Antero, et al. "Hypoxia/ischemia impairs CD33 (Siglec-3)/TREM2 signaling: Potential role in Alzheimer's pathogenesis." Neurochemistry international vol. 150 (2021): 105186. doi: https://doi.org/10.1016/j.neuint.2021.105186
Salminen A, Kaarniranta K, Kauppinen A. Hypoxia/ischemia impairs CD33 (Siglec-3)/TREM2 signaling: Potential role in Alzheimer's pathogenesis. Neurochem Int. 2021 Nov;150:105186. doi: 10.1016/j.neuint.2021.105186. Epub 2021 Sep 13. PMID: 34530055.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 59 entries